Clareo Health | A Pragmatic Trial of Interleukin-17 Inhibition Versus Janus Kinase Inhibition After Tumor Necrosis Factor-alpha Inhibitor Failure in Axial Spondyloarthritis
A Pragmatic Trial of Interleukin-17 Inhibition Versus Janus Kinase Inhibition After Tumor Necrosis Factor-alpha Inhibitor Failure in Axial Spondyloarthritis
The University of Texas Health Science Center, Houston
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
fulfill ASAS classification criteria for axSpA and/or modified New York classification criteria for AS
Active axSpA (ASDAS ≥ 2.1 and/or BASDAI ≥ 4)
Failure of or intolerance to ≥1 TNF
Participants of reproductive potential must agree to use any form of effective contraception during the study period, in accordance with standard clinical practice and FDA labeling for the assigned study medication
Ability to provide informed consent
You may not be if
Previously received an IL-17i or JAKi
Active infection requiring antimicrobials
Contraindications to either treatment arm:
* Inflammatory bowel disease (IBD)- Crohn's disease or Ulcerative Colitis
* Active cancer or cancer remission within the past 3 years (apart from non-melanoma skin cancer (NMSC) and cervical intraepithelial neoplasia (CIN)
* History of stroke, heart attack, or blood clots (venous or arterial)
* Cirrhosis
* End-stage renal disease (GFR \<15) or dialysis
* Human Immunodeficiency Virus (HIV) positive
* Pregnant or lactating
Concomitant use of other biologic or targeted synthetic disease-modifying anti-rheumatic drug (tsDMARD) therapy
